The narrower loss and extended cash runway are positive, but the FDA's requirement for a second Phase 3 trial delays potential NDA submission and commercialization, increasing development costs and dilution risk. Monitor RECOVER-2 trial design and funding needs ahead of mid-2026 initiation.
RVPH drugs
RVPH drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 30 $0.6600entry
- T+1 · 8mo ago +10.61%α +7.72% · $0.7300
- T+5 · 7mo ago +18.18%α +13.88% · $0.7800
- T+20 · 7mo ago +33.33%α +20.74% · $0.8800
- T+60 · 5mo ago −9.09%α −25.58% · $0.6000
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Reviva Pharmaceuticals reported financial results for 2025, showing a reduced net loss of $19.9M compared to $29.9M in 2024, with cash of $14.4M as of year-end. The company received FDA feedback requiring a second Phase 3 trial (RECOVER-2) for brilaroxazine in schizophrenia, planned to start mid-2026, and raised $23M in cash through equity offerings, extending its runway into Q1-2027.
Key Financial Metrics
Key Facts
- Net loss narrowed to $19.9M in 2025 from $29.9M in 2024, with EPS improving from -$17.73 to -$5.48
- Cash and cash equivalents increased to $14.4M as of December 31, 2025, up from $13.5M in 2024
- FDA recommended a second Phase 3 trial (RECOVER-2) for brilaroxazine before NDA submission, delaying potential approval
- RECOVER-2 trial initiation planned for mid-2026, with U.S. enrollment expected to begin in Q3-2026
- Raised $23M in gross proceeds from three public offerings in 2025 and March 2026, giving ~$23M in cash post-March 2026 offering
Financial Impact
Reduced operating expenses by $10.6M YoY, primarily due to lower R&D spending; cash runway extended into Q1-2027
Risk Factors
- Clinical trial delay increases time to potential approval and risk of further regulatory hurdles
- Dilution risk remains elevated given reliance on equity financing and projected cash runway into only Q1-2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264432 |
Track record
12 reports on RVPH
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 No price data
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3400 Now $0.3504 +3.07% settles Feb 11
- Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
- Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
- May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
- May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
- Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
- Mar 30, 202633w ago Press Release Mixed 6/10 Viewing Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
- Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers